AI Benchmarking Underscores Challenges and Opportunities in Neurology Drug Target Discovery

According to a recent LinkedIn post from Insilico Medicine, the company’s ongoing #ScienceAIBench series is now evaluating AI models on their ability to identify clinical-stage drug targets for neurologic disorders. The benchmark focuses on neurodegenerative, neuromuscular, and cerebrovascular indications including Alzheimer’s, ALS, Epilepsy, Huntington’s disease, Multiple Sclerosis, Spinal Muscular Atrophy, and Stroke.

The post highlights comparative performance of leading AI models such as Gemini 2.5 Pro, Claude Opus 4.1, GPT-5, DeepSeek R1, and Grok 4 using Mean Average Precision at TopK as the metric. GPT-5 is described as the leader in complex neurodegenerative and cerebrovascular conditions, while Gemini 2.5 Pro appears strongest in disorders involving neuronal signaling and motor control, and Claude Opus 4.1 stands out for Huntington’s disease.

Insilico’s post also points to a “complexity gap,” where models perform near-perfectly on monogenic-like conditions such as SMA but struggle with heterogeneous diseases like ALS, where the top score remains relatively modest. For investors, this suggests that while AI tools are showing promise in target discovery, particularly for genetically simpler indications, significant technical and biological challenges remain in the more commercially important complex neurodegenerative segment.

The benchmarking activity may indicate Insilico Medicine’s strategic emphasis on positioning itself as a rigorous evaluator and user of advanced foundation models for drug discovery rather than relying on a single model. This comparative framework could strengthen its credibility with pharma partners and investors by demonstrating an evidence-based approach to AI model selection and highlighting areas where incremental model advances might unlock future pipeline opportunities.

If Insilico can translate superior target identification in certain indications into a differentiated preclinical and clinical pipeline, it could enhance the company’s potential value in licensing, partnerships, or future fund-raising. At the same time, the documented difficulty in ALS and similar diseases underscores ongoing execution risk and the likelihood that timelines and costs for AI-enabled neurology programs may remain elevated relative to less complex therapeutic areas.